National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
Topics
- Antibiotics (1)
- Behavioral Health (1)
- Cancer (2)
- Cancer: Ovarian Cancer (1)
- Children/Adolescents (1)
- Community-Based Practice (1)
- Depression (1)
- (-) Genetics (6)
- Health Insurance (1)
- Health Literacy (1)
- Infectious Diseases (1)
- Medication (3)
- Methicillin-Resistant Staphylococcus aureus (MRSA) (1)
- Screening (1)
- Shared Decision Making (1)
- Urinary Tract Infection (UTI) (1)
- Women (1)
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 6 of 6 Research Studies DisplayedZhang K, Potter RF, Marino J
Comparative genomics reveals the correlations of stress response genes and bacteriophages in developing antibiotic resistance of Staphylococcus saprophyticus.
The study explored resistance patterns in Staphylococcus saprophyticus, a common cause of UTIs in women. Genomic analysis linked antibiotic resistance genes to susceptibility, identifying associations with SCCmec configurations and phage elements. This database aids in resistance surveillance for precise diagnosis and treatment, potentially curbing resistance transmission.
AHRQ-funded; HS027621.
Citation: Zhang K, Potter RF, Marino J .
Comparative genomics reveals the correlations of stress response genes and bacteriophages in developing antibiotic resistance of Staphylococcus saprophyticus.
mSystems 2023 Dec 21; 8(6):e0069723. doi: 10.1128/msystems.00697-23..
Keywords: Genetics, Antibiotics, Urinary Tract Infection (UTI), Medication
Gore Moses R, Nieters A, Valentine rKD
Performance of the shared decision-making process scale for use in evaluation of hereditary cancer genetic testing decisions.
This study’s objective was to evaluate the feasibility, acceptability, reliability, and validity of the four-item Shared Decision Making (SDM) Process Scale for use in for hereditary cancer genetic testing decision-making. Participants were patients from a large hereditary cancer genetics practice who responded to an online survey following pre-test genetic counseling; the survey included the SDM Process Scale and the SURE scale. The SDM Process Scale showed feasibility, acceptability, and retest reliability, but not convergent validity with decisional conflict. The authors concluded that their findings provided evidence for use of this scale to measure patient perceptions of SDM in pre-test counseling.
AHRQ-funded; HS025718.
Citation: Gore Moses R, Nieters A, Valentine rKD .
Performance of the shared decision-making process scale for use in evaluation of hereditary cancer genetic testing decisions.
J Genet Couns 2023 Oct; 32(5):957-64. doi: 10.1002/jgc4.1704..
Keywords: Shared Decision Making, Cancer, Genetics
Stallings SC, Richmond SC, Canedo JR
Assessing patient-level knowledge of precision medicine in a community health center setting.
Researchers used a mixed-methods approach to identify patient-level factors that influenced understanding of cancer risk among federally qualified community health center (FQCHC) patients. Participants were English-speaking adults aged 40-79 years enrolled in focus groups; they completed surveys to assess patient-level understanding of precision medicine, numeracy, and health literacy. The findings suggested that patients may lack familiarity with precision medicine concepts relevant for understanding cancer treatment decisions. The researchers concluded that future educational efforts might help to bridge the gap in patient understanding and facilitate equitable opportunities for precision medicine for patients, including those seeking care from community health centers.
AHRQ-funded; HS026122.
Citation: Stallings SC, Richmond SC, Canedo JR .
Assessing patient-level knowledge of precision medicine in a community health center setting.
J Community Genet 2023 Apr; 14(2):197-210. doi: 10.1007/s12687-023-00632-4..
Keywords: Community-Based Practice, Health Literacy, Genetics
McNeil JC, Sommer LM, Vallejo JG
Reduced ceftaroline susceptibility among invasive mrsa infections in children: a clinical and genomic investigation.
The purpose of this study was to assess the frequency of reduced susceptibility (RS) to ceftaroline among pediatric methicillin-resistant Staphylococcus aureus (MRSA) infections. The researchers evaluated MRSA isolates at a tertiary children's hospital for ceftaroline RS. Ceftaroline RS occurred only among health care associated infections in 2.9% of isolates, and were more often clindamycin-resistant.
AHRQ-funded; HS026896.
Citation: McNeil JC, Sommer LM, Vallejo JG .
Reduced ceftaroline susceptibility among invasive mrsa infections in children: a clinical and genomic investigation.
Antimicrob Agents Chemother 2022 Oct 18;66(10):e0074522. doi: 10.1128/aac.00745-22..
Keywords: Children/Adolescents, Medication, Methicillin-Resistant Staphylococcus aureus (MRSA), Infectious Diseases, Genetics
Tuteja S, Salloum RG, Elchynski AL
Multisite evaluation of institutional processes and implementation determinants for pharmacogenetic testing to guide antidepressant therapy.
This paper looked at how sites implement or plan implementation of pharmacogenetic (PGx) testing to guide antidepressant therapy. The authors administered two surveys at 17 sites that had implemented or were in the process of implementing PGx testing for antidepressants. The first survey (Survey 1) collected data on the process and logistics of testing, and the second survey (Survey 2) asked sites to rank the importance of Consolidated Framework for Implementation Research (CFIR) constructs using best-worst scaling choice experiments. Four of the sites were still in the planning stage, 13 offered testing in the outpatient setting, and nine in both outpatient/inpatient settings. PGx tests were mainly ordered by psychiatrists (92%) and primary care (69%) providers. Justification for antidepressants selected for PGx guidance was based on Clinical Pharmacogenetics Implementation Consortium guidelines (94%) and US Food and Drug Administration (FDA; 75.6%) guidance. Both institutional and commercial laboratories were used for testing. Sites were consistent in ranking Consolidated Framework for Implementation Research (CFIR) constructs and identified patient needs/resources, leadership engagement, intervention knowledge/beliefs, evidence strength and quality, and the identification of champions as most important for implementation. Key drivers for implementation were similar across sites and may help guide other institutions interested in providing PGx-guided pharmacotherapy for antidepressant management.
AHRQ-funded; HS026379.
Citation: Tuteja S, Salloum RG, Elchynski AL .
Multisite evaluation of institutional processes and implementation determinants for pharmacogenetic testing to guide antidepressant therapy.
Clin Transl Sci 2022 Feb; 15(2):371-83. doi: 10.1111/cts.13154..
Keywords: Medication, Depression, Behavioral Health, Genetics
Cham S, Landrum MB, Keating NL
Use of germline BRCA testing in patients with ovarian cancer and commercial insurance.
The authors examined commercially insured populations to identify patient-, physician-, and practice-level characteristics associated with ovarian cancer testing rates. They found that only 33.9% of patients with commercial insurance were tested during the time period studied. Medical and gynecologic oncologists had similar rates of testing, while other physicians tested less often. Although independent practices often lack access to genetic counselors, women in this study had insurance coverage for in-person and telephonic counseling.
AHRQ-funded; HS024072.
Citation: Cham S, Landrum MB, Keating NL .
Use of germline BRCA testing in patients with ovarian cancer and commercial insurance.
JAMA Netw Open 2022 Jan 4;5(1):e2142703. doi: 10.1001/jamanetworkopen.2021.42703..
Keywords: Cancer: Ovarian Cancer, Cancer, Screening, Genetics, Health Insurance, Women